Evidence map›Paper›PMID 32347174›Full record

SynthesisJournal of managed care & specialty pharmacy2020

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy.

Jeffrey A Tice, Gregory F Guzauskas, Ryan N Hansen, Serina Herron-Smith, Celia Segel, Judith M E Walsh, Steven D Pearson

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of managed care & specialty pharmacy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Differences in familiarity with oral immunotherapy among caregivers of White and Black children with food allergy.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024
    Article
  4. Review
  5. Food allergy treatment value: Child caregiver and patient perspectives.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021
    Article
  6. New Insights in Therapy for Food Allergy.Foods (Basel, Switzerland) · 2021
    Review
  7. Peanut (The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jeffrey A TiceUniversity of California, San Francisco.
Gregory F GuzauskasThe Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle.
Ryan N HansenThe Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle.
Serina Herron-SmithInstitute for Clinical and Economic Review, Boston, Massachusetts.
Celia SegelInstitute for Clinical and Economic Review, Boston, Massachusetts.
Judith M E WalshUniversity of California, San Francisco.
Steven D PearsonInstitute for Clinical and Economic Review, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

disclosuresFunding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Kaiser Foundation Health Plan, and Partners HealthCare to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Herron-Smith and Pearson are employed by ICER, which has a contract with the University of California, San Francisco, to perform work for these analyses. Segal was employed by ICER at the time of this review. Tice and Walsh are employed by the University of California, San Francisco. Gazauskas and Hansen have nothing to disclose.

Indexed as

ArachisAdministration, CutaneousClinical Trials, Phase III as TopicHumansImmunotherapyPeanut HypersensitivityRandomized Controlled Trials as TopicTreatment Outcome

Identifiers

PMID32347174
PMCPMC10391191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.